Analyzing Nyxoah (NASDAQ:NYXH) & Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ)

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Risk and Volatility

Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Health Sciences Acquisitions Co. 2 and Nyxoah, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Sciences Acquisitions Co. 2	0	0	0	0	0.00
Nyxoah	0	0	5	0	3.00

Nyxoah has a consensus target price of $17.00, suggesting a potential upside of 69.32%. Given Nyxoah’s stronger consensus rating and higher possible upside, analysts clearly believe Nyxoah is more favorable than Health Sciences Acquisitions Co. 2.

Profitability

This table compares Health Sciences Acquisitions Co. 2 and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
Nyxoah	-1,043.93%	-51.68%	-40.11%

Insider & Institutional Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Comparatively, 17.1% of Nyxoah shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Health Sciences Acquisitions Co. 2 and Nyxoah”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A
Nyxoah	$5.08 million	67.29	-$46.77 million	($1.87)	-5.37

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Nyxoah.

Summary

Health Sciences Acquisitions Co. 2 beats Nyxoah on 6 of the 11 factors compared between the two stocks.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.